scispace - formally typeset
D

Donald C. Vinh

Researcher at McGill University Health Centre

Publications -  151
Citations -  11139

Donald C. Vinh is an academic researcher from McGill University Health Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 32, co-authored 118 publications receiving 7052 citations. Previous affiliations of Donald C. Vinh include National Institutes of Health & Aarhus University.

Papers
More filters
Journal ArticleDOI

Autoantibodies against type I IFNs in patients with life-threatening COVID-19.

Paul Bastard, +140 more
- 23 Oct 2020 - 
TL;DR: A means by which individuals at highest risk of life-threatening COVID-19 can be identified is identified, and the hypothesis that neutralizing auto-Abs against type I IFNs may underlie critical CO VID-19 is tested.
Journal ArticleDOI

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Qian Zhang, +172 more
- 23 Oct 2020 - 
TL;DR: The COVID Human Genetic Effort established to test the general hypothesis that life-threatening COVID-19 in some or most patients may be caused by monogenic inborn errors of immunity to SARS-CoV-2 with incomplete or complete penetrance finds an enrichment in variants predicted to be loss-of-function (pLOF), with a minor allele frequency <0.001.
Journal ArticleDOI

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

Nicole M. Kuderer, +239 more
- 20 Jun 2020 - 
TL;DR: The outcomes of a cohort of patients with cancer and COVID-19 are characterised and potential prognostic factors for mortality and severe illness are identified and race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality.
Journal ArticleDOI

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

TL;DR: Tuberculin skin testing (TST) should be undertaken before any significant immunosuppressive therapy including these agents, though the possibility of false-negative reactions in immunocompromised populations must be borne in mind.